価格表

在庫・価格 : 2024年04月20日 12時14分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-Poly(ADP-Ribose), Rabbit-Poly <Anti-PAR Polymer>
データシート※最新のデータシートでない場合があります
4336-BPC-100 RSDアールアンドディー システムス
R&D Systems, Inc.
100 μl 本製品は取扱中止になりました 追加

在庫・価格 : 2024年04月20日 12時14分 現在

Anti-Poly(ADP-Ribose), Rabbit-Poly <Anti-PAR Polymer>

  • 商品コード:4336-BPC-100
  • メーカー:RSD
  • 包装:100μl
  • 本製品は取扱中止になりました
使用文献
No. 文献情報 備考 参照
1 Ordonez LD et al. Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumours. Oncotarget 2019 Apr;10(27):2586-2606
Ordonez LD et al
2019/01/01
PubMed
2 Singatulina AS et al. PARP-1 Activation Directs FUS to DNA Damage Sites to Form PARG-Reversible Compartments Enriched in Damaged DNA. Cell Rep 2019 May;27(6):1809-1821.e5
Singatulina AS et al
2019/01/01
PubMed
3 Wang R et al. Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities. Oncol Lett 2019 Jan;17(1):1217-1222
Wang R et al
2019/01/01
PubMed
4 Cheng H et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013 Apr;34(4):739-49
Cheng H et al
2013/01/01
PubMed
5 Ngo G et al. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget 2018 Dec;9(101):37549-37563
Ngo G et al
2018/01/01
PubMed
6 Li Q et al. Hydrogen&#x2011;rich medium alleviates high glucose&#x2011;induced oxidative stress and parthanatos in rat Schwann cells in&#xA0;vitro. Mol Med Rep 2019 Jan;19(1):338-344
Li Q et al
2019/01/01
PubMed
7 Matveeva EA et al. PARP1 is a versatile factor in the regulation of mRNA stability and decay. Sci Rep 2019 Mar;9(1):3722
Matveeva EA et al
2019/01/01
PubMed
8 Murai J et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012 Nov;72(21):5588-99
Murai J et al
2012/01/01
PubMed
  • No.: 1
  • 文献情報:
    Ordonez LD et al. Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in <i>Brca2</i>-mutant mammary tumours. Oncotarget 2019 Apr;10(27):2586-2606
    Ordonez LD et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Singatulina AS et al. PARP-1 Activation Directs FUS to DNA Damage Sites to Form PARG-Reversible Compartments Enriched in Damaged DNA. Cell Rep 2019 May;27(6):1809-1821.e5
    Singatulina AS et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Wang R et al. Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities. Oncol Lett 2019 Jan;17(1):1217-1222
    Wang R et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Cheng H et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013 Apr;34(4):739-49
    Cheng H et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Ngo G et al. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget 2018 Dec;9(101):37549-37563
    Ngo G et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Li Q et al. Hydrogen&#x2011;rich medium alleviates high glucose&#x2011;induced oxidative stress and parthanatos in rat Schwann cells in&#xA0;vitro. Mol Med Rep 2019 Jan;19(1):338-344
    Li Q et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Matveeva EA et al. PARP1 is a versatile factor in the regulation of mRNA stability and decay. Sci Rep 2019 Mar;9(1):3722
    Matveeva EA et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Murai J et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012 Nov;72(21):5588-99
    Murai J et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed